title: Combine intravitreal bevacizumab with Nd: YAG laser hyaloidotomy for valsalva pre-macular haemorrhage and observe the internal limiting membrane changes: a spectralis study.
abstract: Valsalva retinopathy was described as a particular form of retinopathy, pre-retinal and subinternal limiting membrane haemorrhages in nature that rarely may break through and become subhyloid or intravitreal, secondary to a sudden increase in intrathoracic pressure. We reported a new way that Nd:YAG laser for ILM hyaloidotomy in order to drain the sub-ILM blood into vitreous cavity combined with intravitreal bevacizumab to improve the absorption of blood. Therapeutic alliance make significant outcome, protecting vision in time. We used spectralis OCT to observe sub-ILM mix cells and special ILM structure in this lesion for the first time, as the spectralis OCT can reach histology level imagination.
authors: Department of Ophthalmology, the First Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
authors: Rui
authors: R
authors: Hua
authors: Li-Min
authors: LM
authors: Liu
authors: Yue-Dong
authors: YD
authors: Hu
authors: Yun
authors: Y
authors: Zhou
authors: Lei
authors: L
authors: Chen
keywords: bevacizumab; internal limiting membrane; spectralis OCT; valsalva retinopathy
references: Am J Ophthalmol. 2003 Oct;136(4):763-6
references: 14516831
references: Br J Ophthalmol. 2007 May;91(5):701-2
references: 17446519
references: Trans Am Ophthalmol Soc. 1972;70:298-313
references: 4663671
references: Ir J Med Sci. 2011 Sep;180(3):749-52
references: 19495839
references: Graefes Arch Clin Exp Ophthalmol. 2010 May;248(5):641-50
references: 20012643
references: Ophthalmic Surg Lasers Imaging. 2009 Jan-Feb;40(1):19-24
references: 19205491
references: Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):599-601
references: 19997743